-
The Value of Persistence in Neovascular Age-Related Macular Degeneration
Sep 9, 2025, 16:22 PM -
Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in the US
Sep 9, 2025, 16:22 PM -
The Effect of Pharmaceutical Pricing Policies on Healthcare Expenditures in Turkey: Analysis for the Period 2015-2024
Sep 9, 2025, 16:22 PM -
Evidence Strategy Starts Early: Integrating HTA Needs Through PICO Simulation in Metastatic Castration-Resistant Prostate Cancer
Sep 9, 2025, 16:22 PM -
Market Access AI Readiness: Maximizing Strategic Alignment Through Organizational Insights
Sep 9, 2025, 16:22 PM -
Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements
Sep 9, 2025, 16:22 PM -
A NICE Idea? Assessing the Impact of the Severity Modifier in Oncology and Nononcology Single Technology Appraisals
Sep 9, 2025, 16:22 PM -
Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions
Sep 9, 2025, 16:22 PM -
Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018-2022
Sep 9, 2025, 16:22 PM -
Natural Language Processing for Identification of Negative Symptoms in Patients With and Without Cognitive Impairment Associated With Schizophrenia (CIAS)
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Safety of Targeted NSCLC Therapies Using the FDA Adverse Event Reporting System (FAERS) Differing Experience of Healthcare Providers (HCP) From EU vs. US
Sep 9, 2025, 16:22 PM -
Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Analysis of Abrocitinib vs. Upadacitinib and Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis
Sep 9, 2025, 16:22 PM -
Country-Specific Adaptation of Health Economic Models With Generative AI: A Case Study in Alzheimer’s Disease
Sep 9, 2025, 16:22 PM -
Knowledge and Awareness of Primary Care Physicians (PCPs) Towards Respiratory Syncytial Virus (RSV) in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan
Sep 9, 2025, 16:22 PM -
Assessing the Quality of Hemophilia Care: How Suitable Are Patient-Centered Outcomes to Compare Hospital Performance?
Sep 9, 2025, 16:22 PM -
The Five-Year Budget Impact of Introducing Semaglutide 2.4 mg for Obesity Management in Saudi Arabia: A Real-World Patient Flow and Complication-Driven Model
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK
Sep 9, 2025, 16:22 PM -
A Disease Progression Model Comparing Respiratory and Motor Decline in People With Late-Onset Pompe Disease Treated With Cipaglucosidase Alfa Plus Miglustat vs. Alglucosidase Alfa
Sep 9, 2025, 16:22 PM -
Who Pays the Price? International Impacts of US Drug-Cost Benchmarking
Sep 9, 2025, 16:22 PM
